United Homes Group stock plunges after Nikki Haley, directors resign
Jon Congleton, Chief Executive Officer of Mineralys Therapeutics, Inc. (NASDAQ:MLYS), sold a total of 15,100 shares of common stock on October 13, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sale comes as MLYS trades near its 52-week high of $44.38, having delivered an impressive 252% return year-to-date. InvestingPro analysis indicates the stock is slightly overvalued at current levels. The sales, executed under a pre-arranged 10b5-1 trading plan, totaled $644326.
The transactions involved two separate sales. The first sale consisted of 13,548 shares, sold at a weighted average price of $42.6295, with individual prices ranging from $41.9800 to $42.9800. The second sale involved 1,552 shares, sold at a weighted average price of $43.0299, with individual prices ranging from $42.9822 to $43.2030. With a market capitalization of $3.32 billion and strong analyst support (consensus: Strong Buy), investors can access comprehensive insider trading analysis and 15+ additional key insights through InvestingPro.
Following the reported transactions, Congleton directly owns 831305 shares of Mineralys Therapeutics .
In other recent news, Mineralys Therapeutics, Inc. has completed its public offering, raising approximately $287.5 million in gross proceeds. The offering included over 11 million shares of common stock, which were sold at $25.50 each. Additionally, Mineralys has reported positive subgroup data from its Phase 3 Launch-HTN trial, demonstrating significant blood pressure reductions with its aldosterone synthase inhibitor, lorundrostat, in diverse patient populations. This data was presented at the American Heart Association Hypertension Scientific Sessions. The company has also completed enrollment in its Phase 2 EXPLORE-OSA trial, which aims to evaluate lorundrostat for treating obstructive sleep apnea and hypertension. H.C. Wainwright has reiterated its Buy rating for Mineralys, citing the potential of lorundrostat, and Jefferies has raised its price target for the company to $26, maintaining a Hold rating. These developments highlight the ongoing progress and interest in Mineralys’ drug candidate, lorundrostat.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.